Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

[email protected]

Sheryl Seapy

Pure Communications

[email protected]


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
07:50p W&M PRESS -- HOUSE DEMOCRATS TO PRESIDENT TRUMP : Working Families Are Relying on You to Pay Cost-Sharing Reduction Payments
07:50p DEUTSCHE BANK : Committee Dems Request Information from Deutsche Bank on Russia Money Laundering Scheme and Trump Accounts
07:50p REDX PHARMA : Statement re. Suspension
07:50p OFFICE OF GOVERNOR OF STATE OF LOUISIA : Gov. Edwards Welcomes Vice President Pence to Louisiana
07:50p CONSOLIDATED COMMUNICATIONS : Awards $35,000 in Grants to Schools in Illinois
07:50p CFPB CONSUMER FINANCIAL PROTECTION BUREAU : New information will help U.S. improve financial literacy
07:50p NATIONAL BANK OF KENYA : Former NBK finance chief charged with Sh77m fraud
07:50p MANCHESTER UNITED : Bomber's Blast Felt on Street Where He Grew Up
07:50p SBERBANK ROSSII : reports 1Q 2017 Net Profit of RUB166.6 bn, or RUB7.79 per ordinary share, under International Financial Reporting Standards (IFRS)
07:50p OpenMP ARB Appoints Duncan Poole of NVIDIA and Kathryn O’Brien of IBM to its Board of Directors
Latest news
Advertisement
Hot News 
-29.69%FTSE edges up helped by M&S, but miners weigh
-8.52%TIFFANY : surprise comparable sales drop sends shares tumbling
4.72%Weak sales, supply disruption take toll on Kingfisher
6.03%HAPAG LLOYD : German shipping group Hapag-Lloyd aims for speedy post-merger integration
6.90%BUFFALO WILD WINGS : ISS recommends activist nominees for Buffalo Wild Wings board
Most Read News
06:54a Moody's downgrades China, warns of fading financial strength as debt mounts
04:07a BUNGE : says not in talks with Glencore following approach
09:33a SAFRAN : cuts Zodiac offer by 15 percent to $7.7 billion
10:45a TSX slips as bank stocks weigh
11:07a MARKS AND SPENCER : M&S forecasts recovery in tough market after profit fall
Most recommended articles
05/22 NOBLE : shares tumble after S&P ratings downgrade
01:45pDJTERRENCE DUFFY : CME Chairman and CEO Terrence Duffy Suffers Collapsed Lung
01:35p JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 million
01:31p PHH : U.S. appeals court appears divided in CFPB regulator case
01:28pDJGENERAL ELECTRIC : GE Will Need More Cost Cuts to Hit 2018 EPS Goal, CEO Says